All In Biotech

Free tool

FAERS Monitor: Nipent

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020122 or its brand name (Nipent, Pentostatin). Reports on generic versions are filed under their own applications.

Reports

1,052

Serious

968

92% of reports

Hospitalization

431

Death reported

257

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia78
  • pyrexia72
  • dyspnoea71
  • diarrhoea62
  • drug ineffective62
  • off label use59
  • pneumonia58
  • sepsis57
  • nausea55
  • anaemia54
  • thrombocytopenia54
  • febrile neutropenia48
  • hypotension47
  • renal failure47
  • fatigue45

Reports by year received

View as table
YearReports
200421
200557
200658
200746
200861
200927
201039
201160
201271
201374
201458
201534
201621
201761
201839
201963
202054
202159
202226
202319
202445
202538
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal4814.511.0590
neutropeniaSignal7811.59.3740
sepsisSignal5710.27.9467
thrombocytopeniaSignal549.77.4413
renal failureSignal477.15.4241
anaemiaSignal545.74.4204
hypotensionSignal474.73.5134
pyrexiaSignal724.23.3173
pneumoniaSignal583.62.8107
dyspnoeaSignal712.52.065
diarrhoea621.91.527
nausea551.41.16
off label use591.31.15
fatigue451.20.91
drug ineffective620.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.